Valeant Has Big Plans To Become A Big Pharma In Coming Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.
You may also be interested in...
Is Valeant The Fix to Salix Inventory Woes?
The Canadian pharma is willing to bet $14.5 billion that it can take care of the specialty pharma’s stocking level issues and still pull in $500 million in synergies with in the first six months.
Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.
Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.